PepGen Inc.
PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugatedā¦ read more
Healthcare
Biotechnology
1 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.85
Price+5.02%
$0.23
1Y
Price
Market Cap
$159.138m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$1.492m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$96.915m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$2.96
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$71.158m
$102.242m
Assets$31.084m
Liabilities$17.864m
DebtDebt to Assets
17.5%
-0.2x
Debt to EBITDAFree Cash Flow
-$90.599m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company